
    
      This study will evaluate efficacy, therapeutic effects, tolerability and safety of CBD oil in
      adults with SAD through a randomized placebo-controlled study design and will evaluate
      effects of CHI-902 on peripheral endocannabinoids (AEA and 2-AG). This study will be the
      first randomized, double-blind placebo-controlled trial conducted with CHI-902 in adults with
      SAD.

      The study is designed to:

        -  Evaluate the efficacy of CHI-902 versus placebo in adults with SAD.

        -  Evaluate the tolerability and safety versus placebo of CHI-902 in adults with SAD.

        -  Explore the effects of CHI-902 versus placebo on different biomarkers in subjects with
           SAD.
    
  